Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium longum FGSZY6M4
- Development stage
- Preclinical
- Lead developer
- Jiangnan University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium longum FGSZY6M4 is a live biologic therapeutic consisting of a specific probiotic bacterial strain, Bifidobacterium longum subspecies longum, being researched for the treatment of constipation. It was selected from the Culture Collection of Food Microorganisms at Jiangnan University in China and is registered under a Chinese patent (ZL113943682A). Preclinical research in rats with loperamide-induced constipation showed that FGSZY6M4 was the most effective among three tested strains, with an optimal dose delivered via colon-released capsules. Its mechanism of action involves regulating gastrointestinal peptides like motilin (MTL), gastrin (GAS), and vasoactive intestinal peptide (VIP), as well as aquaporin-3 and 5-hydroxytryptamine levels. This modulation improves fecal water content and promotes intestinal motility. No commercial developer has been identified.
- Other names
- 长双歧杆菌 FGSZY6M4
02
Targets
5-HT (Serotonin receptors)MLNR (Human motilin receptor)AQP3 (Aquaporin-3 channel protein)
Beyond the preview
Go deeper on bifidobacterium longum FGSZY6M4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium longum FGSZY6M4.